564476-26-2

Upstream product

• 32981-86-5 10-deacetylbaccatin III 
• 194720-19-9 7,10,13-tris(triethylsilyl)-10-deacetylbaccatin III 
• 994-30-9 triethylsilyl chloride 
• 2785-98-0 2,5-dimethoxybenzoic acid 
• 204580-30-3 10-O-deacetyl-2-O-debenzoyl-7,10,13-O-tris(triethylsilyl)baccatin III 

Downstream Products

• 564476-30-8 C₆₀H₉₅NO₁₇Si₂ 
• 564476-31-9 7-(triethylsilyl)-2'-(triisopropylsilyloxy)-3'-dephenyl-3'-(isobutenyl)-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-docetaxel 
• 564476-28-4 C₃₇H₅₄O₁₂Si 
• 653587-09-8 C₆₂H₈₇NO₁₆SSi₂ 
• 653586-90-4 10-acetoxy-7-(triethylsilyl)-2'-(triisopropylsilyloxy)-3'-dephenyl-3'-(2-furyl)-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-docetaxel 
• 653587-11-2 C₆₀H₈₅NO₁₇SSi₂ 
• 653586-87-9 C₅₉H₈₇NO₁₇Si₂ 
• 653587-08-7 C₆₀H₈₉NO₁₆SSi₂ 
• 653586-91-5 C₆₀H₈₅NO₁₈Si₂ 
• 653587-07-6 C₅₉H₈₇NO₁₆SSi₂ 
• 653587-10-1 C₆₀H₉₁NO₁₇SSi₂ 
• 653586-89-1 C₆₂H₈₇NO₁₇Si₂ 
• 653586-75-5 C₆₀H₉₃NO₁₆Si₂ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors

The use of drug-antibody conjugates affords a method for the targeted delivery of anticancer drugs specifically to cancer cells. Monoclonal antibodies alone usually do not possess high therapeutic efficacy, however, they are capable of targeting tumor mar

Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies

The targeted delivery of taxoids, in the form of taxane-antibody immunoconjugates, requires the preparation of taxoids containing moieties suitable for their conjugation to monoclonal antibodies. A series of taxoids incorporating a disulfide-containing li